Tango Therapeutics reports strong Phase 1/2 pancreatic cancer data, plans Phase 3 trial in 1H 2027 with $977.5M cash.

Tango Therapeutics announced promising Phase 1/2 results for its pancreatic cancer treatment combining vopimetostat and daraxonrasib, showing an 82% response rate and 88% progression-free survival at nine months. The company plans to start a Phase 3 trial in the first half of 2027 targeting front-line MTAP-deleted pancreatic cancer, aiming for regulatory approval. Tango also revealed a $977.5 million cash position as of September 2026 to support ongoing development. Additional lung cancer data and new combination studies are expected in early 2027, highlighting the company's focus on PRMT5-targeted therapies.

Tango Therapeutics holds a market cap of $3.62 billion and an enterprise value of $2.64 billion as of November 9, 2026, 19:02 WIB. The stock price on Pluang is USD 21.75, showing a modest gain of 1.16% on the day. Trading volume reached 2,129,303 shares, with investors typically holding the stock for about 4 days. This data provides context to the company's strong clinical progress and cash position highlighted in the recent financial results.